Regadenoson in the detection of coronary artery disease

Buhr, Christiane; Gössl, Mario; Erbel, Raimund; Eggebrecht, Holger

doi:10.2147/vhrm.s1798

Cited by 24 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Regadenoson, 23 (Lexiscan ® ), is the only A2A receptor agonist that has been approved by the FDA (Figure 6B). Regadenoson is a pyrazole derivative of adenosine that induces coronaries dilatation by binding to A2A receptors of the coronary arteries [110,111]. Regadenoson is more than 100 times more potent than adenosine as an agonist of A2A receptor.…”

Section: Specific A2a Receptor Agonistmentioning

confidence: 99%

Adenine, a key player in biology and medicinal chemistry

Fillion,

Vichier-Guerre,

Arimondo

2024

Comptes Rendus. Chimie

View full text Add to dashboard Cite

Adenine is one of the most ubiquitous heterocycles in life. In addition of being one of the four nucleobases constituting DNA and RNA, adenine is also contained in many biological molecules (ATP, SAM, NAD, cAMP, coA . . . ) that have fundamental roles in the functioning of living systems, e.g. energy source, cofactors of enzymes and proteins. As such, the adenine has naturally become a privileged scaffold explored in medicinal chemistry for biomedical applications. Many chemical modifications and Structure-Activity Relationships studies have been carried out on the adenine scaffold to result in potent analogues with various biological activities. Today, numerous adenine-based inhibitors are used to treat a wide range of diseases including cancer, viral and bacterial diseases. This review aims to introduce the adenine and discuss adenine-based inhibitors, their design and use for different therapeutic targets through examples of drugs and compounds that reached clinical and preclinical trials.

show abstract

Section: Specific A2a Receptor Agonistmentioning

confidence: 99%

Adenine, a key player in biology and medicinal chemistry

Fillion,

Vichier-Guerre,

Arimondo

2024

Comptes Rendus. Chimie

View full text Add to dashboard Cite

show abstract

“…Combining CCTA and CT-MPI allows for a single-modality approach for the anatomic and functional evaluation of CAD. Dynamic CT-MPI shows similar diagnostic accuracy compared with other techniques, including SPECT, invasive fractional flow reserve (FFR), cardiac magnetic resonance imaging (CMR), and invasive coronary angiography 2–11. The main advantage of CT-MPI is the ability to absolutely quantify blood flow, in contrast to SPECT and MRI.…”

mentioning

confidence: 98%

“…Dynamic CT-MPI shows similar diagnostic accuracy compared with other techniques, including SPECT, invasive fractional flow reserve (FFR), cardiac magnetic resonance imaging (CMR), and invasive coronary angiography. [2][3][4][5][6][7][8][9][10][11] The main advantage of CT-MPI is the ability to absolutely quantify blood flow, in contrast to SPECT and MRI. Whereas (CT-)FFR only yields functional information on a lesion specific level, CT-MPI enables the detection of global perfusion defects caused by microvascular disease, 3-vessel disease or hypertension, and diabetes.…”

mentioning

confidence: 99%